KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Revenue (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Revenue for 10 consecutive years, with $864000.0 as the latest value for Q4 2025.

  • Quarterly Revenue fell 97.58% to $864000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2025, down 90.59% year-over-year, with the annual reading at $3.5 million for FY2025, 90.59% down from the prior year.
  • Revenue hit $864000.0 in Q4 2025 for CRISPR Therapeutics AG, down from $889000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $900.7 million in Q2 2021 to a low of $6000.0 in Q4 2022.
  • Historically, Revenue has averaged $69.9 million across 5 years, with a median of $865000.0 in 2025.
  • Biggest five-year swings in Revenue: tumbled 99.98% in 2022 and later surged 3353333.33% in 2023.
  • Year by year, Revenue stood at $12.9 million in 2021, then tumbled by 99.95% to $6000.0 in 2022, then soared by 3353333.33% to $201.2 million in 2023, then crashed by 82.26% to $35.7 million in 2024, then crashed by 97.58% to $864000.0 in 2025.
  • Business Quant data shows Revenue for CRSP at $864000.0 in Q4 2025, $889000.0 in Q3 2025, and $892000.0 in Q2 2025.